XtalPi, a Chinese AI drug discovery firm, said on October 29 that it had partnered with Singapore’s Agency for Science, Technology and Research (A*STAR).

Under the MARVEL-AI program, the companies will develop new materials using computational tools and automated laboratory experiments.

The collaboration will cover laboratory automation, joint research facilities, materials discovery, and talent exchange under the A*STAR-led program.

Anchored by A*STAR’s Institute of Materials Research and Engineering, MARVEL-AI targets industrial uses in semiconductors, energy, and advanced chemicals.

The deal expands XtalPi’s relationship with Singapore’s Experimental Drug Development Centre, A*STAR’s national drug discovery platform.

The company said the relationship began in 2022. That work included AI-enabled drug discovery for non-small cell lung cancer.

🔗 Source: XtalPi Inc.